Biotech Values

[DewDiligence]

ENTA RSV—These are ancillary data to accompany the results reported in Jun 2019 (#msg-149386027); the full PR is at:

https://www.enanta.com/investors/news-releases/press-release/2019/New-Data-from-Enantas-Phase-2a-Human-Challenge-Study-of-EDP-938-for-RSV-Demonstrates-Highly-Statistically-Significant-Reductions-p0001-in-Total-Symptom-Score-Mucus-Weight-and-RSV-Viral-Load-as-Measured-by-RT-PCR-Assay-and-by-Plaque-Assay/default.aspx